Kinome profiling of TNBC tumours suggests that ERK2 is activated compared to control tissue, while ERK1 activity remains unchanged [94], and it is tempting to speculate that the hypoxic tumour environment drives in vivo ERK2 activation. This evidence concerns the gene MAPK3 and neoplasm.